We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Estrogen receptor downregulates programmed death ligand-1 and associated with clinicopathological of type 1 endometrial carcinoma.
- Authors
Waluyo, Setyo Teguh; Tjokroprawiro, Brahmana Askandar
- Abstract
Objective: To determine the correlation between estrogen receptor (ER) and programmed death ligand-1 (PD-L1) expression with clinicopathological of type 1 endometrial carcinoma. Methods: This was a retrospective study with a cross-sectional design. Spearman's rank test was used to assess the correlation of ER with PD-L1 and the Fisher Exact test used to evaluate the association between ER, PD-L1 and the clinicopathological characteristics of type 1 endometrial carcinoma. Results: The positivity rates of ER and PD-L1 in type 1 endometrial cancer were 68.2% and 78.5%, respectively. ER have strongly negative correlation with PD-L1 in type 1 endometrial cancer (rho=-0.886) and (p-value <0.05). ER positivity was significantly associated with body mass index (BMI) ≥25, premenopausal status, early stage of disease, <1/2 myometrial invasion, negative nodal metastasis, and lack of adjuvant therapy. It was also associated with age <55 years, low-grade cells, and angiolymphatic invasion, but the correlation was not significant. Meanwhile, PD-L1 positivity was significantly associated with BMI <25, menopausal status, advanced stage of disease, highgrade cells, angio-lymphatic invasion, and adjuvant therapy. It was also associated with age ≥55 years and nodal metastasis, but the correlation was not significant. Conclusion: ER downregulates PD-L1 in type 1 endometrial cancer. ER and PD-L1 positivity are associated with the clinicopathological characteristics of type 1 endometrial carcinoma.
- Subjects
ESTROGEN receptors; ENDOMETRIAL cancer; CLINICAL pathology; FISHER exact test; BODY mass index
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, p17
- ISSN
2005-0380
- Publication type
Article
- DOI
10.3802/jgo.2024.35.S2.O4